Search Nerddpedia

Heart Failure

** Heart failure (HF), also called congestive heart failure (CHF), is a clinical syndrome in which the heart cannot pump enough blood to meet the body’s metabolic needs or does so only at the cost of elevated filling pressures. **CONTENT:** ## Overview Heart failure is not a single disease but a **syndrome** that results from structural or functional cardiac abnormalities that impair the heart’s ability to **fill** (diastolic dysfunction) or **eject** (systolic dysfunction) blood efficiently. The condition may develop gradually over years, as in chronic hypertension or coronary artery disease, or present abruptly after a massive myocardial infarction. Patients typically experience **dyspnea**, **fatigue**, **edema**, and reduced exercise tolerance, reflecting the body’s attempt to compensate for inadequate circulation. Compensatory mechanisms—such as activation of the renin‑angiotensin‑aldosterone system (RAAS) and sympathetic nervous system—temporarily preserve perfusion but eventually lead to maladaptive remodeling, worsening the heart’s performance. HF is classified by **ejection fraction (EF)**: - **HF with reduced EF (HFrEF)**: EF ≤ 40%, reflecting impaired systolic contraction. - **HF with preserved EF (HFpEF)**: EF ≥ 50%, where diastolic filling is the primary problem. - **HF with mildly reduced EF (HFmrEF)**: EF 41‑49%, an intermediate category. Because symptoms overlap with many other conditions, a thorough evaluation—including history, physical exam, **echocardiography**, natriuretic peptide testing, and sometimes cardiac MRI—is essential. **If you experience persistent shortness of breath, swelling of the ankles, or unexplained fatigue, seek medical evaluation promptly**, as early diagnosis improves outcomes. ## History/Background The concept of “heart failure” dates back to ancient Greek physicians such as **Hippocrates**, who described “dropsy” (fluid accumulation) as a sign of a weak heart. In the 19th century, **William Osler** coined the term “congestive heart failure” after observing pulmonary congestion in patients with advanced cardiac disease. The invention of the **electrocardiogram (ECG)** in the early 1900s and the development of **cardiac catheterization** in the 1940s allowed clinicians to measure cardiac pressures directly, confirming the hemodynamic basis of HF. A pivotal moment arrived in the 1970s with the **Framingham Heart Study**, which identified hypertension, myocardial infarction, and valvular disease as major risk factors. The 1980s saw the first large‑scale trials of **ACE inhibitors** (e.g., enalapril) demonstrating mortality reduction, establishing pharmacologic blockade of the RAAS as a cornerstone of therapy. The 1990s introduced **beta‑blockers** and **spironolactone**, further improving survival. More recent milestones include the **PARADIGM‑HF trial (2014)** showing the benefit of the angiotensin‑neprilysin inhibitor sacubitril/valsartan, and the **2021 FDA approval of SGL‑inhibitors** (e.g., dapagliflozin) for HF regardless of diabetes status. ## Key Information - **Epidemiology:** Over 64 million people worldwide live with HF; prevalence rises sharply after age 65. In the United States, HF accounts for ~1 million hospitalizations annually and a 5‑year mortality of ~50 % after diagnosis. - **Etiology:** Common causes include ischemic heart disease, hypertension, cardiomyopathies (dilated, hypertrophic, restrictive), valvular lesions, and arrhythmias. Lifestyle factors—obesity, excessive alcohol, and uncontrolled diabetes—also contribute. - **Diagnostic Criteria:** The **2022 ACC/AHA/HFSA guideline** emphasizes a combination of symptoms, signs, and objective evidence of cardiac dysfunction (e.g., EF < 50 % or elevated natriuretic peptides). - **Management:** A multi‑modal approach is standard: 1. **Pharmacologic therapy**—ACE inhibitors/ARBs/ARNI, beta‑blockers, mineralocorticoid receptor antagonists, SGL‑inhibitors, and diuretics for volume control. 2. **Device therapy**—implantable cardioverter‑defibrillators (ICDs) for sudden death prevention, cardiac resynchronization therapy (CRT) for dyssynchrony, and left ventricular assist devices (LVADs) for end‑stage disease. 3. **Lifestyle interventions**—salt restriction, fluid limitation, regular aerobic exercise, smoking cessation, and weight management. 4. **Advanced care**—heart transplantation or palliative care when refractory. - **Prognosis:** Early, guideline‑directed therapy can reduce mortality by 30‑40 % and improve quality of life. However, recurrent hospitalizations remain common, underscoring the need for close follow‑up and patient education. ## Significance Heart failure represents a **major public health challenge** due to its high prevalence, costly hospitalizations, and substantial morbidity. Economically, HF accounts for an estimated **$30 billion** in annual U.S. healthcare expenditures, with a growing burden as populations age. Clinically, HF serves as a **sentinel indicator** of underlying cardiovascular disease, prompting aggressive risk‑factor modification that benefits overall heart health. Advances in pharmacology, device engineering, and telemonitoring have transformed HF from a uniformly fatal condition into a manageable chronic disease for many patients. Nonetheless, disparities persist—racial and socioeconomic groups experience higher incidence and poorer outcomes, highlighting the need for equitable access to care and culturally competent education. **When to seek professional care:** If you notice new or worsening shortness of breath (especially when lying flat), sudden weight gain (> 2 kg in a few days), swelling of the legs or abdomen, or a persistent cough, contact a healthcare provider immediately. Early intervention can prevent decompensation and reduce the risk of life‑threatening complications. **INFOBOX:** - Name: Heart Failure (Congestive Heart Failure) - Type: Cardiovascular syndrome / Chronic disease - Date: First described as “congestive heart failure” in the late 19th century (circa 1885) - Location: Global (affects populations worldwide) - Known For: Impaired cardiac filling and/or ejection leading to systemic and pulmonary congestion **TAGS:** heart failure, congestive heart failure, cardiology, ejection fraction, hypertension, myocardial infarction, ACE inhibitors, cardiac remodeling